IGI Logo

Below is quote on should investors apply for the upcoming IPO after week listing of Windlas biotech IPO by Mr. Yash Gupta, Equity Research Associate, Angel Broking Ltd   

After a week listing for Windlass Biotech, should investors apply for the upcoming IPOs?

Windlas Biotech got listed at a 4.5% discount to its issue price of ₹460, despite the IPO getting a good response from investors and getting oversubscribed by more than 22 times. Currently, the stock is trading at ₹392 which is down by 14.7% from its IPO price.

Earlier, we have seen some of the IPOs getting listed at discount to its IPO price like Macrotech Developers and after the listing, the stock has recovered and given good returns to investors. This was on the back of good fundamentals and recovery in the sector.

We suggest investors look at the fundamentals of the company before applying to an IPO, as we have seen that companies having good fundamentals give good returns on listing day or after the listing.

For the upcoming IPOs, we suggest investors be cautious as a lot of the upcoming IPOs are at aggressive valuations. We believe that a company having good fundamentals along with it being priced at reasonable valuations improves the chances of getting listing gains significantly.

Above views are of the author and not of the website kindly read disclaimer